COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 05 2023
Historique:
received: 26 05 2022
accepted: 26 04 2023
medline: 29 5 2023
pubmed: 26 5 2023
entrez: 25 5 2023
Statut: epublish

Résumé

The physiological effects of vaccination against SARS-CoV-2 (COVID-19) are well documented, yet the behavioural effects not well known. Risk compensation suggests that gains in personal safety, as a result of vaccination, are offset by increases in risky behaviour, such as socialising, commuting and working outside the home. This is potentially important because transmission of SARS-CoV-2 is driven by contacts, which could be amplified by vaccine-related risk compensation. Here, we show that behaviours were overall unrelated to personal vaccination, but-adjusting for variation in mitigation policies-were responsive to the level of vaccination in the wider population: individuals in the UK were risk compensating when rates of vaccination were rising. This effect was observed across four nations of the UK, each of which varied policies autonomously.

Identifiants

pubmed: 37231004
doi: 10.1038/s41598-023-34244-2
pii: 10.1038/s41598-023-34244-2
pmc: PMC10209557
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8441

Subventions

Organisme : Department of Health
ID : NIHR200915
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/22
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 110110/Z/15/Z
Pays : United Kingdom

Investigateurs

Tina Thomas (T)
Daniel Ayoubkhani (D)
Russell Black (R)
Antonio Felton (A)
Megan Crees (M)
Joel Jones (J)
Lina Lloyd (L)
Esther Sutherland (E)
Emma Pritchard (E)
Karina-Doris Vihta (KD)
George Doherty (G)
James Kavanagh (J)
Kevin K Chau (KK)
Stephanie B Hatch (SB)
Daniel Ebner (D)
Lucas Martins Ferreira (LM)
Thomas Christott (T)
Wanwisa Dejnirattisai (W)
Juthathip Mongkolsapaya (J)
Sarah Cameron (S)
Phoebe Tamblin-Hopper (P)
Magda Wolna (M)
Rachael Brown (R)
Richard Cornall (R)
Gavin Screaton (G)
Stuart Cox (S)
Kevin Paddon (K)
Tim James (T)
Thomas House (T)
Julie Robotham (J)
Paul Birrell (P)
Helena Jordan (H)
Tim Sheppard (T)
Graham Athey (G)
Dan Moody (D)
Leigh Curry (L)
Pamela Brereton (P)
Ian Jarvis (I)
Anna Godsmark (A)
George Morris (G)
Bobby Mallick (B)
Phil Eeles (P)
Jodie Hay (J)
Harper VanSteenhouse (H)
Jessica Lee (J)
Sean White (S)
Tim Evans (T)
Lisa Bloemberg (L)
Katie Allison (K)
Anouska Pandya (A)
Sophie Davis (S)
David I Conway (DI)
Margaret MacLeod (M)
Chris Cunningham (C)
Katrina Lythgoe (K)
David Bonsall (D)
Tanya Golubchik (T)
Helen Fryer (H)

Informations de copyright

© 2023. The Author(s).

Références

Lancet. 2021 Jun 26;397(10293):2461-2462
pubmed: 34139198
Lancet Public Health. 2021 Jan;6(1):e30-e38
pubmed: 33308423
J Epidemiol Community Health. 2022 Feb;76(2):109-115
pubmed: 34244309
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
Clin Infect Dis. 2018 Aug 16;67(5):676-686
pubmed: 29509889
Nat Med. 2021 Dec;27(12):2127-2135
pubmed: 34650248
Hum Vaccin Immunother. 2016 Jun 2;12(6):1435-50
pubmed: 26864126
JAMA Netw Open. 2021 Oct 1;4(10):e2131137
pubmed: 34698850
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nat Med. 2021 Sep;27(9):1614-1621
pubmed: 34244681
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
BMJ. 2021 Aug 20;374:n1943
pubmed: 34417165
PeerJ. 2019 May 27;7:e6876
pubmed: 31179172
BMJ. 2006 Mar 11;332(7541):605-7
pubmed: 16528088
Curr Med Res Opin. 2022 Dec;38(12):2021-2028
pubmed: 36106710
Ann Intern Med. 2021 Jun;174(6):858-859
pubmed: 33646837
BMJ. 2020 Jul 26;370:m2913
pubmed: 32713835
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274

Auteurs

John Buckell (J)

Health Economics Research Centre, Richard Doll Building, Old Road Campus, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK. john.buckell@ndph.ox.ac.uk.
Health Behaviours, Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK. john.buckell@ndph.ox.ac.uk.
The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. john.buckell@ndph.ox.ac.uk.

Joel Jones (J)

Office for National Statistics, Newport, UK.

Philippa C Matthews (PC)

The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.
Division of Infection and Immunity, University College London, Gower St, London, WC1E 6BT, UK.
Department of Infection, University College London Hospitals, 235 Euston Rd, London, NW1 2BU, UK.

Sir Ian Diamond (SI)

Office for National Statistics, Newport, UK.

Emma Rourke (E)

Office for National Statistics, Newport, UK.

Ruth Studley (R)

Office for National Statistics, Newport, UK.

Duncan Cook (D)

Office for National Statistics, Newport, UK.

Ann Sarah Walker (AS)

The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Nuffield Department of Medicine, University of Oxford, Oxford, UK.
The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.
MRC Clinical Trials Unit at UCL, UCL, London, UK.

Koen B Pouwels (KB)

Health Economics Research Centre, Richard Doll Building, Old Road Campus, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH